Between now and the UK’s departure from the EU at the end of March 2019, the European Medicines Agency may have to reassign as many as 230 human-use medicines for which the country has acted as rapporteur or co-rapporteur in the centralized approvals procedure. This is just under one in four of the almost 1,000 medicines approved centrally since the current system came into operation in 1995.
There are also questions over how far the UK can continue to be chosen as the lead or co-lead regulator...
